← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Panacos Pharmaceuticals, Inc.
Gaithersburg, MD
$6,342,345
Total funding
9
Grants
Funding mix
By agency
NIH$6,342,345 · 9
By mechanism
R44$4,322,862 · 4
R01$1,060,000 · 1
R43$959,483 · 4
Investigators at Panacos Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of DSB, a novel potent HIV inhibitor$840,027
R44 · FY2004 · AI
Development of DSB, a novel potent HIV inhibitor$783,893
R44 · FY2003 · AI
Development of DSB, a novel potent HIV inhibitor$575,847
R44 · FY2005 · AI
NATURAL PRODUCT DERIVATIVES THAT POTENTLY INHIBIT HIV-1$437,061
R44 · FY2002 · AI
NATURAL PRODUCT DERIVATIVES THAT POTENTLY INHIBIT HIV-1$430,491
R44 · FY2001 · AI
Blood Filter to Remove Pathogen Inactivation Compound$402,386
R44 · FY2004 · HL
Identification of Small Molecule Inhibitors of RSV Entry$370,130
R44 · FY2004 · AI
Small Molecule HIV Fusion Inhibitors$298,099
R43 · FY2003 · AI
Small Molecule HIV Fusion Inhibitors$295,257
R43 · FY2004 · AI
Blood Filter to Remove Pathogen Inactivation Compound$284,595
R44 · FY2005 · HL
VIRALLY INACTIVATED HUMAN RED CELLS FOR TRANSFUSION$265,000
R01 · FY2001 · HL
VIRALLY INACTIVATED HUMAN RED CELLS FOR TRANSFUSION$265,000
R01 · FY2003 · HL
VIRALLY INACTIVATED HUMAN RED CELLS FOR TRANSFUSION$265,000
R01 · FY2004 · HL
VIRALLY INACTIVATED HUMAN RED CELLS FOR TRANSFUSION$265,000
R01 · FY2002 · HL
Blood Filter to Remove Pathogen Inactivation Compound$198,432
R44 · FY2003 · HL
Identification of Small Molecule Inhibitors of RSV Entry$143,045
R43 · FY2002 · AI
DEVELOPMENT FOR DSB, A NOVEL POTENT HIV INHIBITOR$125,591
R43 · FY2002 · AI
DP-178, A GP41 PEPTIDE-BASED HIV-1 VACCINE$97,491
R43 · FY2000 · AI